WO2006022428A1 - 糖尿病治療剤 - Google Patents
糖尿病治療剤 Download PDFInfo
- Publication number
- WO2006022428A1 WO2006022428A1 PCT/JP2005/015956 JP2005015956W WO2006022428A1 WO 2006022428 A1 WO2006022428 A1 WO 2006022428A1 JP 2005015956 W JP2005015956 W JP 2005015956W WO 2006022428 A1 WO2006022428 A1 WO 2006022428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- insulin
- agent
- inhibitor
- hypoglycemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- the present invention relates to an agent for increasing the insulin content useful for the treatment of diabetes and the like.
- Background Art It is known that not only type 1 but also type 2 diabetes (fasting blood glucose: FPG> 126 mg / dL), the amount of knee cells is markedly reduced. It has already been observed in IFG (Impaired Fasting Glucose) (110 ⁇ FPG ⁇ 125 mg / dL), where fasting blood glucose is slightly above normal. Knee] 3 cell mass is histologically positive for insulin; 8 cell mass is quantified, whereas knee insulin content is knee 3 cell mass and insulin contained in individual / 3 cells It is thought to reflect the amount. Therefore, a drug that actively increases the insulin content, which reflects the amount of knee cells and the amount of insulin contained in each individual [3] cell, is considered effective for the fundamental treatment of diabetes.
- knee J3 cells are regulated by the death and replication of j3 cells and cell death due to apoptosis.
- knee cells are exhausted and eventually knee cell death is enhanced. Therefore, a drug that increases the knee insulin content, and further has a protective effect such as suppression of fatigue and ⁇ / 3-cell death is considered to be extremely effective in the treatment of diabetes.
- DPP-IV dipeptidyl peptidase IV
- DPP-IV dipeptidyl peptidase IV
- WO02Z062764 pamphlet and international Refer to pamphlet No. W02004Z 014860
- DPP-IV inhibitors are known to be used in combination with antidiabetic compounds (for example, International Publication No. W001 / 52825 pamphlet and US patent). (See Japanese Patent Application No. 2003/0166578).
- An object of the present invention is to provide an insulin content increasing agent that is useful for the treatment of diabetes and the like and has no side effects.
- the present inventors have found for the first time that a combination of a DPP-IV inhibitor and a non-insulin secretion-type hypoglycemic agent can provide an unexpectedly excellent knee insulin content increasing effect, and completed the present invention. It came to do.
- Knee-insulin content-increasing agent comprising a combination of a non-insulin-secreting hypoglycemic agent and a dipeptidyl peptidase IV inhibitor;
- a method for increasing the content of knee insulin in a mammal comprising administering a non-insulin secretory hypoglycemic agent and a dipeptidyl peptidase IV inhibitor to the mammal;
- the non-insulin secretion type hypoglycemic drug is an insulin resistance improving drug.
- a method for enhancing the knee protective action of a dipeptidyl peptidase IV inhibitor in a mammal which comprises administering a non-insulin secretion type hypoglycemic drug to the mammal;
- a method of enhancing the sputum protective action of a non-insulinotropic hypoglycemic agent in a mammal which comprises administering a dipeptidyl peptidase IV inhibitor to the mammal;
- a non-insulin secretion type hypoglycemic agent and a dipeptidyl peptidase IV inhibitor are administered to a mammal, and synergistically compared to single administration of these drugs How to protect the viscera;
- the insulin content increasing agent of the present invention has an excellent effect of increasing knee insulin content and is useful for the treatment of diabetes and the like.
- the agent for increasing the insulin content and the knee protecting effect enhancer of the present invention exhibits an excellent blood glucose lowering effect and blood insulin level increasing action for diabetic patients, and further diabetic complications (eg, diabetes mellitus). Neuropathy, diabetic nephropathy, diabetic retinopathy, arteriosclerosis).
- the knee insulin content-increasing agent and the knee protecting effect-enhancing agent of the present invention are sugar It suppresses knee fatigue caused by urinary glucotoxicity, lipotoxicity, oxidative stress or endoplasmic reticulum stress, and iii) retains the sugar-dependent insulin secretion ability, which is an important function of 3 cells.
- the knee insulin content-enhancing agent and knee-protecting effect-enhancing agent of the present invention can suppress sputum cell death due to diabetes, and can promote the neoplasia or replication of the knee; 3 cells.
- the sputum insulin content-enhancing agent and knee-protecting effect-enhancing agent of the present invention induces sugar-dependent promotion of insulin secretion, but the side effects of insulin preparations (eg, vascular complications, hypoglycemia), sulfonylurea It does not have the side effects (eg knee fatigue, hypoglycemia) of insulin secretory hypoglycemic agents that act on rare receptors. Therefore, the knee insulin content-increasing agent and knee protecting effect-enhancing agent of the present invention can be safely administered over a long period to patients suffering from diabetes.
- a non-insulin secretion-type hypoglycemic agent means a compound that lowers blood glucose by an action mechanism other than the insulin secretory action from 3 cells.
- the compound may be either peptide or non-peptide, but is preferably non-peptide.
- the form of the non-insulin secretion type hypoglycemic drug may be different before and after administration to the living body as long as the non-insulin secretion type hypoglycemic activity is retained. That is, the non-insulin secretory hypoglycemic drug may be an “active metabolite” having non-insulin secretory hypoglycemic activity after undergoing in vivo metabolism to form a structural change. Furthermore, the non-insulin secretory hypoglycemic drug may be a “prodrug” that is converted into an active form by a reaction with an enzyme, gastric acid, or the like under physiological conditions in vivo.
- non-insulin-secreting hypoglycemic agents include, for example, insulin-inhibiting drug, biguanide, somatostatin receptor agonist, 11-hydride Examples include roxistroid dodehydrogenase inhibitors and ⁇ -darcosidase inhibitors. Two or more of these may be used in combination at an appropriate ratio.
- insulin sensitizers examples include piodaritazone or a salt thereof (preferably hydrochloride), rosiglitazone or a salt thereof (preferably maleate), Regl ixane (JTT-501), netoglitazone
- T-131 or a salt thereof THR-0921 and the like.
- thiazolidinedione compounds are preferable, and piodaritazone or a salt thereof (preferably hydrochloride) is preferable.
- biguanides examples include metformin, phenformin, buformin, or salts thereof (eg, hydrochloride, fumarate, succinate). Of these, metformin or a salt thereof (preferably hydrochloride) is preferable.
- somatostatin receptor agonists examples include compounds described in W001 / 25228, W003 / 42204, TO98 / 44921, W098 / 45285, W099 / 22735, and the like. Of these, somatostatin subtype 2 receptor agonists are preferred.
- Hydrocysteloid dodehydrogenase inhibitors include BVT-3498, for example.
- ⁇ -darcosidase inhibitor examples include voglibose, calcalose, miglitol, emidatetate and the like.
- the non-insulin secretion type hypoglycemic agent is preferably an insulin resistance improving agent and a biguanide agent, more preferably an insulin resistance improving agent, and particularly preferably pioglitazone or a salt thereof (preferably hydrochloride).
- a DPP-IV inhibitor means a compound that inhibits the enzyme activity of DPP-IV [Classification by United Nations Biochemical Nomenclature Committee (IUBMB): EC3.4.1.4.15].
- the compound may be either peptidic or non-peptidic, but is preferably non-peptidic.
- DPP-IV inhibitor retains DPP-IV inhibitory activity, its form may be different before and after administration in vivo. That is, the DPP-IV inhibitor may be an “active metabolite” having DPP-IV inhibitory activity after it has undergone in vivo metabolism to become a structural change body. Furthermore, DPP-IV inhibitors may be “prodrugs” that are converted to active forms by reactions with enzymes, gastric acid, etc. under physiological conditions in vivo.
- the DPP-IV inhibitory activity can be confirmed by a method using, for example, the method of “Raymond et al. (Diabetes, 47, 1253-1258, 1998)”.
- Specific examples of the DPP-IV inhibitor include the following compounds (1) to (6). Two or more of these may be used in combination at an appropriate ratio.
- a ring is an optionally substituted 5- to 10-membered aromatic ring
- R 1 and R 2 are the same or different and each represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- X represents a bond, 1 O—, 1 S—, 1 SO—, — S 0 2 — or — NR 3 — (R 3 represents a hydrogen atom or an optionally substituted hydrocarbon group);
- L represents a divalent hydrocarbon group] or a salt thereof.
- a pharmacologically acceptable salt is preferable.
- examples of such a salt include a salt with an inorganic base, a salt with an organic base, and an inorganic acid. Salts with organic acids, salts with basic or acidic amino acids, and the like.
- Suitable examples of salts with inorganic bases include alkali metal salts such as sodium salt and potassium salt; alkaline metal salts such as calcium salt and magnesium salt; aluminum salt; Etc.
- salts with organic bases include trimethylamine, triethylamine, pyridine, picolin, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N-dibenzylethylenediamine, etc. And the salt.
- salt with inorganic acid examples include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- the salt with organic acid include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, malic acid, methanesnorephonic acid, benzene sulphonic acid, p- And salts with tonorensnorephonic acid.
- salt with basic amino acid examples include salts with arginine, lysine, ornithine and the like.
- salt with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
- the compound represented by the formula (I) may be non-hydrated, hydrated, or prodrug.
- the compound represented by the following compounds :
- C w which may be substituted with a carbamoyl group or a carboxyl group, respectively.
- An alkyl group preferably ethyl
- An alkenyl group preferably etyr
- An optionally substituted hydroxyl group [preferably having 1 to 3 substituents selected from a strong rubamoyl group, a carboxyl group, and an alkoxycarbonyl group having 2 to 5 carbon atoms (preferably methoxycarbonyl).
- a C 1-10 alkoxy group (preferably methoxy, isopropoxy); a hydroxyl group; a C 7-13 arraloxy group (preferably benzyloxy)] [more preferably Is a force ruby moyl methoxy];
- Amino group which may be substituted (preferably carbamoylamino) 6) an optionally substituted thiol group [preferably an alkylthio group having 1 to 10 carbon atoms which may be substituted with a strong rubamoyl group (preferably methylthio)];
- An optionally substituted heterocyclic group [preferably a C 1 M alkyl group optionally substituted with 1 to 3 halogen atoms (preferably methyl, trifluoromethyl), a carboxyl group, a carbon number of 2 to 8 alkoxycarbonyl groups (preferably ethoxycarbonyl), cyano groups, strong rubamoyl groups, amino groups, mono- or di-C w.
- Alkanoylamino group eg, acetylamino, isopentanoylamino
- alkoxy monofunctional group eg, methoxycarbonylamino
- carbamoylamino group mono- or di-C w .
- Alkyl one-strength ruberamoylamino group eg, methylcarbamoylamino, dimethylcarbamoylamino
- C 6 — 14 aryl-carbonylamino group eg, benzoylamino
- C ⁇ Cycloalkyl one carbo - Ruamino group, C 7 - 13 Ararukiruokishi one carbonyl ⁇ amino group, mono- one or di- one.
- Al Kill sulfonyl ⁇ amino group e.g., methylsulfonyl ⁇ Mino, dimethylsulfoxide - Ruamino
- C 6 _ 14 Arirusuruho - Ruamino group and CH alkoxy Ichiriki Rubamoiruamino group e.g., main butoxy carbamoyl ⁇ Mino
- Aromatic heterocyclic group preferably furyl, chenyl, oxazolyl, oxadiazolyl, thiazolyl, tetrazolyl, pyridyl, pyrrolyl, triazolyl
- non-aromatic heterocyclic group which may have one substituent each
- dioxoisoindole 5-oxoxaziazo, 3-yl, 5-oxothiadiazole-3-yl)]];
- a benzene ring optionally having 1 to 2 substituents selected from:
- R 1 is an alkyl group having 4 to 10 carbon atoms (preferably isobutyl, neopentyl) or a cycloalkylalkyl group having 4 to 10 carbon atoms (preferably cyclopropylmethyl);
- R 2 is a halogen atom (preferably fluorine or chlorine) and alkyl (preferably Preferably 1 to 2 substituents selected from methyl) and an aryl group having 6 to 14 carbon atoms (preferably phenyl);
- X is a bond
- L is CH.
- an alkoxycarbonyl group having 2 to 8 carbon atoms preferably ethoxycarbonyl
- a carbamoyl group preferably ethoxycarbonyl
- An alkyl group preferably ethyl
- An alkenyl group preferably ethenyl
- an optionally substituted hydroxy group [preferably an alkoxy group having 1 to 10 carbon atoms (preferably methoxy) which may be substituted with a strong rubamoyl group; more preferably carbamoyl methoxy];
- an acyl group (preferably carpamoyl, thiocarpamoyl, carboxyl);
- An optionally substituted heterocyclic group preferably, a 6 alkyl group (preferably methyl), a carboxyl group, an alkoxycarbonyl group having 2 to 8 carbon atoms (preferably ethoxycarbonyl), a cyano group, a strong rubermoyl group , amino group, mono- or di-one C 2 _ 10 Arca noisy Rua amino group (e.g., Asechiruamino, isopentanoyl Noi Rua Mino), CH.
- a 6 alkyl group preferably methyl
- a carboxyl group preferably a carboxyl group
- an alkoxycarbonyl group having 2 to 8 carbon atoms preferably ethoxycarbonyl
- a cyano group e.g., a strong rubermoyl group
- amino group e.g., Asechiruamino, isopentanoyl Noi Rua Mino
- Alkoxy one carbonyl ⁇ amino group (e.g., main butoxycarbonyl ⁇ mino) force Rubamoiruamino group, mono- or di-primary alkyl Ichiriki Rubamoiruamino group (e.g., methyl Scarpa moil ⁇ amino, dimethyl Scarpa Moyle ⁇ mino) ⁇ 6 _ 14 Ariru A monocarbonylamino group (eg, benzoylamino), C ⁇ . Cycloalkyl one carbonyl ⁇ amino group, C 7 _ 13 Ararukiruokishi one carbonyl ⁇ amino group, mono- one or di- one.
- Alkynyl Le sulfonyl ⁇ amino group 1 selected from (eg, methylsulfonyl ⁇ amino, dimethyl sulfonyl Ruamino), Ji 6 _ 14 ⁇ reel sulfonyl ⁇ amino group and a C alkoxy Ichiriki Rubamoiruamino group (e.g., main butoxy carbamoyl ⁇ Mino) Na
- an aromatic heterocyclic group which may have two substituents (preferably furyl, chael, oxazolyl, oxadiazolyl, thiazolyl, tetrazolyl, pyridyl, pyrrolyl, triazolyl) or non-aromatic heterocyclic ring Group (preferably 5-oxoxadiazo 1-yl)];
- a benzene ring optionally having 1 to 2 substituents selected from:
- Ri is an alkyl group having 4 to 10 carbon atoms (preferably isoptyl or neopentyl) or a cycloalkylalkyl group having 4 to 10 carbon atoms (preferably cyclopropylmethyl);
- R 2 may be substituted with 1 to 3 halogen atoms, and the alkyl group has 1 or 10 carbon atoms (preferably butyl);
- X is — o—
- L is CH.
- a compound that is alkylene preferably one CH 2 —;
- the compounds represented by the formula (I) 2— [3- (aminomethyl) 1-4 _butoxy _ 2—isobutyl 1-oxo 1, 2-dihydro _ 6-isoquinolyl] — 1, 3 _ Thiazonore 1 4-Canolevonitrinore;
- R 4 is a hydrogen atom or - 6 alkyl group indicates a);
- R 5 is a hydrogen atom, a fluorine atom, _ 6 alkyl group, Shiano group, a nitro group, one oR 4, - CO 2 R 4 or a COR 4 a (R 4 is as defined above);
- R 6 represents a phenyl group, a hydroxyl group, one OR 4 , one OC OR 4 or a benzyloxy group (R 4 is as defined above);
- D represents an optionally substituted amino acid residue Or a salt thereof.
- _ 6 alkyl group represented by R 4 for example methyl, Echiru, propyl, isopropyl Honoré, heptyl, Isobuchinore, sec. Buchinore, t -.
- Puchinore, Penchinore, Isopenchinore, Neopenchinore, 1 Echinorepuro Examples include pinole, hexinole, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.
- Amino acids in the “optionally substituted amino acid residue” represented by D examples include groups obtained by removing OH of a carboxyl group constituting these amino acids from ⁇ -amino acids or j3-amino acids.
- ⁇ -amino acids include, for example, alanine, arginine, asparagine, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methyoen, phenol / lealanine, proline, serine, threonine, tryptophan, Examples include tyrosine, parin, citrulline, ornithine, and homocystine.
- 3-amino acid for example,] 3-alanine, jS-aminocyclopropanoic acid, j8-aminocyclobutanoic acid, j3-aminocyclopentanoic acid, ⁇ -aminocyclohexanoic acid, j3-aminocycloheptanoic acid, j3- And aminocyclooctanoic acid.
- the -amino acid may have an unsaturated bond in the carbon chain constituting the amino acid.
- the -amino acid and j8-amino acid described above may be any of D-form, L-form and DL-form, but natural L-form is preferred.
- the amino acid residue may have 1 to 2 substituents on the amino group or amino acid side chain constituting the amino acid.
- hydrocarbon group in the "optionally substituted hydrocarbon group” for example - 6 alkyl group, _ 12 cycloalkyl, C 2 _ 6 alkenyl group, _ 12 Kuroarukeniru groups, C 2 - 6 alkyl - le group, C 4 - 12 cycloalkadienyl group, C 6 _ 14 Ariru group (preferably Hue sulfonyl group), C 7 - 15 Ararukiru group (preferably base Njiru group, phenethyl group), Adamanchiru group, bicyclo [2.2.1] heptyl group, Bisiku mouth [3.1.1] heptyl group and the like.
- the hydrocarbon group may have 1 to 3 substituents at substitutable positions, such as a halogen atom (preferably fluorine or chlorine); a cyan group; hydroxyl group which may be substituted with Ashiru group; human Dorokishi methyl; 1 to 3 halogen atoms (preferably fluorine) substituted by _ 6 may be alkoxy; optionally substituted Yo Le, C 6 _ 14 reel or Examples thereof include an amino group which may be mono- or disubstituted with an optionally substituted heterocyclic group.
- a halogen atom preferably fluorine or chlorine
- a cyan group preferably cyan group
- hydroxyl group which may be substituted with Ashiru group
- 1 to 3 halogen atoms (preferably fluorine) substituted by _ 6 may be alkoxy
- optionally substituted Yo Le, C 6 _ 14 reel or Examples thereof include an amino group which may be mono- or disubstituted with an optionally substituted hetero
- acyl group in the “hydroxyl group that may be substituted with an acyl group” examples include, for example, the acyl group exemplified as the substituent of the A ring in the aforementioned compound (I 1 a).
- heterocyclic group in the “optionally substituted heterocyclic group” examples include a pyridyl group, a pyrimidyl group, a birazyl group, a quinolyl group, an isoquinolyl group, and a quinoxalyl group.
- the C 6 — 14 aryl group and the heterocyclic group may have 1 to 3 substituents at substitutable positions.
- substituents include halogen atoms (preferably fluorine, chlorine, Bromine); cyano group; nitro group; _ 6 alkyl group; optionally substituted with 1 to 3 halogen atoms (preferably fluorine) — 6 alkoxy group; carboxyl group; carbamoyl group; _ 6 alkylsulfonyl group ( preferably methanesulfonyl group); _ 6 mono- or is an alkyl group di-one optionally substituted Aminosuruhoniru group (preferably like dimethylamino sulfonyl group).
- the substituent in the “optionally substituted hydrocarbon group” is particularly preferably a 5-nitro-2-pyridylamino group, 5-cyan-2-pyridylamino group, 2-pyrimidylamino group, 2-bilazylamino group, etc. It is.
- the number of substituents is, for example, 1 to 3.
- Examples of the “substituent on the amino acid side chain” include an optionally substituted hydrocarbon group, hydroxyl group, 1 to 3 halogen atoms (preferably fluorine). It may have been replaced with ⁇ , ⁇ . Examples thereof include an alkoxy group, an acyl group and an optionally substituted amino group.
- hydrocarbon in the “hydrocarbon group which may be substituted” for example —i. Alkyl group, c 3 - 12 cycloalkyl group,. Alkenyl groups, such as c 3 _ 12 cycloalkenyl group.
- the hydrocarbon group may have 1 to 3 substituents at substitutable positions.
- substituents include an amino group and a 6- alkyl monocarbolamino group (preferably Acetylamino group), hydroxy group, 16 alkoxy group, heterocyclic group (preferably pyridyl) and the like.
- the “acyl group” is preferably a nitrogen-containing heterocyclic-carbonyl group which may be substituted.
- the “optionally substituted nitrogen-containing heterocycle” include a halogen atom (preferably fluorine, chlorine, bromine), a cyano group, a nitro group, and 1 to 3 halogen atoms (preferably fluorine).
- 1-6 alkyl groups eg, trifluoromethyl group
- — 6 alkoxy groups amino groups that may be mono- or di-substituted with 6 alkyl groups, hydroxyl groups, carboxyl groups, and C r _ 6 nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from alkyloxycarbonyl groups (preferably pyridine, pyridazine, pyrimidine, pyrazine, imidazole, pyrazonorole, thiazonole, isothiazole ⁇ / , Oxazonole, isoxazonole) and the like.
- alkyloxycarbonyl groups preferably pyridine, pyridazine, pyrimidine, pyrazine, imidazole, pyrazonorole, thiazonole, isothiazole ⁇ / , Oxazonole, isoxazonole
- substituent in the above-mentioned “optionally substituted amino group” include a substituent selected from a strong ruxoxyl group, a strong rubermoyl group, a 6- alkyl monooxycarbonyl group, and a nitrogen-containing heterocyclic group (preferably pyridyl).
- substituents include an alkyl group having 1 to 3 groups and 6 alkyl groups. These substituents may be bonded to a hydroxyl group, a carboxyl group, an amino group or the like on the amino acid side chain.
- Examples of the salt of the compound represented by the formula (II) include the same salts as the salt of the compound represented by the formula (I).
- the compound represented by the formula (II) may be non-hydrated or hydrated.
- a suitable example of a compound represented by the formula ( ⁇ ) that may be a prodrug is
- thiazolidine or pyrrolidine derivatives such as L-alio-isoleucil thiazolidine, L-threo-isoleucyl pyrrolidine, L-alio-isoleucil pyrrolidine, L-valyl pyrrolidine (described in W001 / 72290 etc.);
- a salt thereof preferably phosphate, hydrochloride
- ⁇ -431, Sitagliptin phosphate a salt thereof (preferably phosphate, hydrochloride) ( ⁇ -431, Sitagliptin phosphate).
- a ring is an optionally substituted 5- to 10-membered aromatic ring
- R 7 and R 8 are the same or different and each represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,
- X a and Y a are the same or different, and are a bond, one O—, one S—, one SO one, one SO 2 — or one NR 9 — (R 9 is a hydrogen atom or an optionally substituted carbon atom) A hydrogen group);
- L a represents a divalent hydrocarbon group. Or a salt thereof.
- Examples of the salt of the compound represented by the formula (III) include those of the compound represented by the formula (I). The thing similar to a salt is mentioned.
- the compound represented by the formula ( ⁇ ) may be a non-hydrate, a hydrate, or a prodrug.
- Preferable examples of the compound represented by the formula (III) include the following compounds.
- a a ring is
- a halogen atom eg, fluorine, chlorine, bromine, iodine
- an alkylenedioxy group having 1 to 3 carbon atoms eg, methylenedioxy
- hydroxy group [eg, halogen atom; carboxyl group and alkoxycarbonyl group having 2 to 5 carbon atoms (eg, tert-butoxy)
- a carbamoyl group optionally substituted with 1 or 2 substituents selected from an alkyl group (eg, methyl, ethyl, propyl, isopropyl) and an alkylsulfur group (eg, methylsulfol); a hydroxy group; alkylcarbonyl ⁇ amino group (e.g., Asechiru amino) of carbon atoms 2-5; carboxyl group; amino alkyl group (e.g., methyl, Echiru) and C 2 - 8 alkoxy carbo - Le group (e.g., main butoxycarbonyl, An aromatic heterocyclic group which may be substituted with 1 to 3 substituents selected from ethoxycarboyl (eg, furyl, chenyl, oxazolyl, thiazolyl, isoxazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl); and A cycloalkyl group having 3 to 10 carbon atom
- alkoxy group having 1 to 10 carbon atoms eg, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy
- a cycloalkyloxy group having 3 to 10 carbon atoms eg, cyclopentyloxy
- carbon number 7 to 13 aralkyloxy groups eg, benzyloxy
- hydroxyl groups eg, benzyloxy
- an optionally substituted amino group [e.g., Amino, mono- one or di- one C 2 - 10 alkylcarbonyl ⁇ amino (e.g., Asechiruamino, propionyl Rua Mino, isopropoxy Tano I Rua Mino, isopentanoyl noisy Rua Mino), Alkoxy one force rubonylamino (eg, methoxycarbolamino), force ruberamoylamino, mono- or dialkyl one force ruberamoamino (eg, methylcarpamoylamino, dimethylcarpamolyamino), C 6 _ 14 7 reel one carbonylamino (eg, benzoylamino) ), C w.
- Amino mono- one or di- one C 2 - 10 alkylcarbonyl ⁇ amino
- Alkoxy one force rubonylamino eg, methoxycarbolamino
- force ruberamoylamino mono
- Cycloalkyl one carbo - Le Amino e.g., cyclopentylcarbonyl ⁇ Mino
- Ji 7 _ 13 Ararukiruokishi - carbonyl ⁇ amino (e.g., benzyl O propoxycarbonyl El ⁇ Mino), mono- or is Gee.
- Alkylsulfonylamino eg, methylsulfonylamino, dimethylsulfonylamino
- C 6 — 14 arylsulfo-lumino eg, phenylsulfonylamino
- Alkoxy-powerful ruberamoylamino eg, methoxycarbamoylamino
- Carpamoyl Primary alkyl amino e.g., Scarpa carbamoylmethyl ⁇ Mino
- C 2 _ 5 alkoxycarbonyl - Lou ⁇ Bok 10 alkyl amino eg, main butoxycarbonyl methyl ⁇ amino, tert- butoxycarbonyl two Rumechiruamino
- An optionally substituted cycloalkyl group having 3 to 10 carbon atoms [eg, C 1-6 alkyl group optionally substituted by 1 or 3 halogen atoms (eg, methyl, trifluoro) Methyl), a carboxyl group, an a ⁇ / coxycarbonyl group having 2 to 8 carbon atoms (eg, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl), a cyano group, a carbamoyl group, an amino group, a mono- or di-one.
- Alkylcarbonylamino groups eg, acetylamino, isopentanoylamino
- An alkoxy monocarbonylamino group eg, methoxy) Carbonylamino
- carpamoylamino group mono- or di-.
- Al Kill Ichiriki Rubamoiruamino group e.g., methylcarbamoyl ⁇ amino, dimethyl Scarpa Moyle ⁇ Mino
- c 6 _ 14 Ariru one carbonyl ⁇ amino group e.g., benzo Iruamino
- Araruki Ruokishi one carbonyl ⁇ amino group, mono- or di-primary alkyl sulfo - Ruamino group e.g., methylsulfonyl ⁇ Mino, dimethylsulfoxide El ⁇ Mino
- An optionally substituted thiol group eg, an alkylthio group having 1 to 10 carbon atoms that may be substituted with a strong rubamoyl group (eg, methylthio)];
- Heterocyclic group which may be substituted [eg, alkyl group which may be substituted with 1 to 3 halogen atoms (eg, methyl, trifluoromethyl), carboxyl group, alkoxy having 2 to 8 carbon atoms A carbonyl group (eg, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-ptoxycarbonyl), a cyano group, a strong rubamoyl group, an amino group, a mono group or a di group.
- Alkylcarbonylamino groups eg, acetylamino, isopentanoylamino
- alkoxy monocarbonylamino group eg, methoxycarbonylamino
- a carbamoylamino group mono- or di-C w .
- Alkyl Ichiriki Rubamoiruamino group e.g., methylcarbamoyl ⁇ amino, dimethyl Scarpa Moyle ⁇ Mino
- C 6 - 14 Ariru one carbonyl ⁇ amino group e.g., Benzoiruamino
- Ji 3 _ 10 cycloalkyl one carbonyl ⁇ amino group, C 7 — 13- aralkyloxy-carbonylamino group, mono- or di-one.
- Alkyl sulfonylamino groups eg, methylsulfonylamino, dimethylsulfonylamino), 6 — 14 arylsulfonylamino groups, alkoxy monocarbamoylamino groups (eg, methoxycalpamoylamino), 2 to 5 carbon atoms Alkylcarbonyl groups (eg, acetyl) and carbamoyl—C- 6 alkyl groups
- An aromatic heterocyclic group which may have one or two substituents selected from (for example, carbamoylmethyl) (preferably furyl, chenyl, oxazolyl, oxadiazolyl, thiazolyl, tetrazolyl, pyridyl , Pyrrolyl, triazolyl) or a non-aromatic heterocyclic group (preferably dioxoisoindole-2-yl; 5-oxoxazodiazole 3-yl;
- a benzene ring optionally having 1 or 2 substituents selected from:
- R 7 is an alkyl group having 3 to 10 carbon atoms (preferably isoptyl) or an alkyl group having 4 to 10 carbon atoms (preferably propyl methyl).
- R 3 is a halogen atom (eg, fluorine, chlorine), a hydroxyl group, a nitro group, an amino group, an optionally halogenated alkyl group having 1 to 6 carbon atoms (eg, trifluoromethyl, methyl), a carbon number 1 to 3 selected from 1 to 6 alkoxy groups (eg, methoxy), aromatic heterocyclic groups (eg, quinolyl, chenyl) and cycloalkyl groups having 3 to 10 carbon atoms (eg, cyclopentyl) Preferably 1 or 2) each having a substituent of 1 to 10 carbon atoms (eg, methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl, tert- Butyl, pentyl), aryl groups having 6 to 14 carbon atoms (eg, phenyl) or araquinol groups having 7 to 13 carbon atoms (eg, benzyl,
- X a is a bond
- L a A compound which is alkylene;
- R 1 Q and R are the same or different and each represents an optionally substituted hydrocarbon group or an optionally substituted hydroxy group
- R 12 represents an optionally substituted aromatic group
- R 13 represents an optionally substituted amino group
- L b is a divalent chain hydrocarbon group
- Q is a bond or a divalent chain hydrocarbon group
- X b represents a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group, or an optionally substituted cyclic group. Indicates.
- Examples of the salt of the compound represented by the formula (IV) include the same salts as the salt of the compound represented by the formula (I).
- the compound represented by the formula (IV) may be a non-hydrate, a hydrate, or a prodrug.
- Preferable examples of the compound represented by the formula (IV) include the following compounds. (Compound IV ')
- R 11 are the same or different, (1) C 3 _ 1 Q cycloalkyl group (preferably cyclopropyl), C -! 6 alkoxy one carbonyl group, to 1 selected from a C Bok 6 alkoxy group three It may be substituted with a substituent.
- Alkyl group; (2) a halogen atom, a carboxyl group, C ⁇ 6 alkoxy one carbonyl group, to 1 selected from such Karupamoiru group 3 may be substituted with a substituent C 6 _ 14 Ariru group (preferably Hue - Le); or (3) C 7 _ 13 Ararukiru group (preferably benzyl);
- R 12 may be substituted with 1 to 3 halogen atoms.
- R 13 is an amino group (preferably an amino group) optionally mono- or di-substituted with an alkyl group;
- Lb is Ci-i. Alkylene (preferably one CH 2 —);
- Q is the joining hand.
- (S ⁇ C ⁇ are also be non-aromatic heterocyclic ring (rather preferably optionally substituted by e alkyl group O Kisoji O Kiso Lil, Okiso one Jiokisoraeru, Okiso one 2- Benzofu Rael) Single Ci_ 6 alkoxy monocarbonyl group; (3f) P 7 — 13 7 aralkyloxy carbonyl group optionally substituted with a substituent selected from a carboxyl group, a strong rubamoyl group, a thiocarbamoyl group and an alkoxy monocarbonyl group; (3g) a carbamoyl group mono- or di-substituted with 1-6 alkyl groups optionally substituted with 1 to 3 halogen atoms and a substituent selected from Ci-e alkoxy groups; (3i) an alkyl group, which may be substituted with 3 halogen atoms and may be mono- or di-sub
- pyrrolidinyl, piperidino, piperazine - Le, morpholino one carbonyl group
- a halogen atom which may be substituted C 6 _ 14 Ariru - nitrogen-containing heterocyclic (preferably pyrrolidinyl, piperidino, piperazinyl, morpholino) one carbonyl group
- (3q) which may be substituted by a halogen atom C 7 _ 13 Ararukiru one nitrogen-containing heterocycle (preferably pyrrolidinyl, piperidino, piperazinyl, morpholino) one carbonyl group
- a non-aromatic heterocycle Preferably, oxodioxolyl, oxodioxanyl, oxo-1-benzofuranyl) oxy-carbonyl group; or (3s) each may be mono- or di-substituted with an alkyl group A phosphono group;
- An alkylamino group (preferably methoxycarbonylmethylamino, ethoxycarbonylmethylamino, tert-ptoxycarbonylmethylamino); (6c) carboxyl i.
- Tetrazolyl oxomidazolidinyl (preferably 2-oxomidazolidinyl 1-yl), dioxoimidazolidinyl (preferably 2,4-dioxoimidazolidin-3-yl ), Oxopiperazinyl (preferably 3-oxopiperazine 1-yl), dioxopiperazine (preferably 2,3-dioxopiperazine _ 1 yl, 2, 5-dioxo Piperazine 1-yl) or oxodihydroxadiazolyl (preferably 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl);
- the compound represented by the formula (IV) can be produced according to a method known per se, for example, the method described in detail below or a method analogous thereto.
- L b is L ba (CH 2 ) (L ba is a bond or a divalent chain hydrocarbon group), 13 is 13 & (X ba is a hydrogen atom, a nitro group, An acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group), and R 13 is an amino group.
- Compound (IV-1) can be produced by the following method A or a method analogous thereto.
- examples of the divalent chain hydrocarbon group represented by L b a include the same groups as those described above for L b.
- L b a is preferably a bond or an alkylene.
- acyl group represented by Xba the substituted hydroxy group, the optionally substituted thiol group, the optionally substituted amino group and the optionally substituted cyclic group are each represented by the above X b The same as is used.
- compound (IV-1) is produced by subjecting compound (IVa) to a reduction reaction. To do.
- the reduction reaction is performed according to a conventional method in the presence of a reducing agent in a solvent that does not adversely influence the reaction.
- the reducing agent examples include metal hydrides such as bis (2-methoxyethoxy) aluminum bismuthium hydride and disobutylaluminum hydride; sodium borohydride, sodium cyanoborohydride, hydrogen hydride Metal hydrogen complex compounds such as minium lithium and aluminum hydride sodium;
- the amount of the reducing agent to be used is generally 0.1 to 20 molar equivalents relative to compound (IVa).
- solvents that do not adversely influence the reaction include alcohols such as methanol, ethanol, propanol, 2-pronool, butanol, isobutanol and tert-butanol; aromatic hydrocarbons such as benzene, toluene and xylene Aliphatic hydrocarbons such as hexane and heptane; Ethers such as Jetinoreethenore, Diisopropinoleetenore, tert-Ptynolemethinoleetenole, Tetrahydrofuran, Dioxane, Dimethoxetane; Methyl acetate, Ethyl acetate Esters such as n-butyl acetate, tert-butyl acetate; Amides such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone are used. Two or more of these solvents may be mixed at an appropriate ratio.
- the reaction temperature is usually _70 to 1550 ° (: preferably _20 to 100 ° C).
- the reaction time is usually from 0.1 to 100 hours, preferably from 0.1 to 40 hours.
- the reduction reaction is a solution that does not adversely affect the reaction in the presence of a metal catalyst such as palladium-carbon, palladium black, palladium chloride, platinum oxide, platinum black, platinum-palladium, Raney nickel, Raney cobalt, and a hydrogen source. It can also be carried out in a medium.
- a metal catalyst such as palladium-carbon, palladium black, palladium chloride, platinum oxide, platinum black, platinum-palladium, Raney nickel, Raney cobalt, and a hydrogen source. It can also be carried out in a medium.
- the amount of the metal catalyst to be used is generally 0.001 to 100 mol equivalent, preferably 0.01 to 100 mol equivalent, relative to compound (IVa). -
- Examples of the hydrogen source include hydrogen gas, formic acid, formic acid amine salt, phosphinic acid salt, and hydrazine.
- Examples of the solvent that does not adversely influence the reaction include those exemplified in the reduction reaction using the reducing agent.
- reaction temperature and reaction time are the same as in the reduction reaction using the reducing agent.
- This reaction may be carried out in the presence of ammonia (eg, aqueous ammonia, ammonia ethanol) if necessary.
- ammonia eg, aqueous ammonia, ammonia ethanol
- side reactions can be suppressed and compound (IV-1) can be produced in high yield.
- the compound (IV-1) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography, etc. it can.
- Compound (IVa) used as a starting compound in Method A can be produced according to a method known per se.
- a compound (IVa-1) in which Q and L ba are a bond and X ba is an acyl group in the formula (IVa) can be produced by the following method B.
- Compound (IVa-1) can be obtained by a method known per se, for example, by reacting compound (IVb) with an oxidizing agent such as dilute nitric acid or diammonium nitrate, and reacting 1,4-dioxane It can be produced by reacting in a solvent that does not adversely affect.
- an oxidizing agent such as dilute nitric acid or diammonium nitrate
- the compound (IVb) can be obtained by a method known per se, for example, Maruzen Publishing Co., Ltd. 1 97 3 “New Experimental Chemistry Course Edition (The Chemical Society of Japan)” Vol. 14 Synthesis and reaction of organic compounds
- the compound can be produced from compound (IVc) and compound (IVf) by Hantzch's pyridine synthesis method described on page 27 or by a method analogous thereto.
- Compound (IVc) can be produced by a method known per se, for example, by subjecting compound (IVd) and compound (IVe) to the known Knoe Venage 1 method.
- Compound (IVf) is a method known per se, for example, the method described in Synthesis, (1999), Vol. 11, 1951–1960 Sada; Journal of Chemical Society Perkin Transactions ⁇ , (2002:!, Pages 1663-1671, etc. It can be produced from compound (IVg) according to a method equivalent thereto.
- the compound (IVd), compound (IVe) and compound (IVg) described above can be produced according to a method known per se.
- R 1 3 is Compound (IV-2), which is an amino group mono- or di-substituted with an alkyl group, can be obtained by subjecting compound (IV-3) in which R 13 is an amino group in formula (IV) to an alkylation reaction. Can be manufactured.
- This reaction is carried out according to a conventional method. (1) In the presence of a base, if necessary, in a solvent that does not adversely influence the reaction using an alkylating agent, or (2) In the presence of a reducing agent, if necessary.
- the carbonyl compound is used in a solvent that does not adversely influence the reaction.
- Alkylating agent for example.
- Alkyl halide i. Examples thereof include alkyl sulfonic acid esters.
- Examples of the carboxylic compound include aldehyde and ketone.
- the amount of the alkylating agent optocarbonyl compound used is preferably about 1 to about 5 molar equivalents relative to compound (IV-3).
- the base examples include alkali metal salts such as sodium hydroxide and potassium carbonate; amines such as pyridine and triethylamine; metal hydrides such as sodium hydride; and alkali metal alkoxides such as sodium methoxide and potassium t.-ptoxide. Etc.
- the amount of the base used is preferably about 1 to about 5 mole equivalents relative to compound (IV-3).
- Examples of the reducing agent include metal hydrogen compounds such as diisoptyl aluminum hydride; metal hydrogen complex compounds such as sodium cyanoborohydride; and the like.
- the amount of the reducing agent to be used is generally 0.1 to 20 molar equivalents relative to compound (IV-3).
- the reaction using the carbonyl compound can also be carried out in the presence of a metal catalyst such as palladium monocarbon and a hydrogen source in a solvent that does not adversely affect the reaction, without using a reducing agent.
- a metal catalyst such as palladium monocarbon and a hydrogen source in a solvent that does not adversely affect the reaction, without using a reducing agent.
- the amount of the metal catalyst to be used is preferably 0.01 to 100 molar equivalents relative to compound (IV-3).
- Examples of the hydrogen source include hydrogen gas, formic acid, formate salt, and the like. '
- the reaction temperature is preferably about 10 to about 100 ° C.
- the reaction time is usually about 0.5 to about 20 hours.
- the compound (IV-2) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography, etc. .
- the raw material compound has an amino group, a carboxyl group, a hydroxyl group or a carbonyl group as a substituent.
- These groups may be introduced with a protecting group generally used in peptide chemistry and the like, and the desired compound can be obtained by removing the protecting group as necessary after the reaction.
- the protecting group of the Amino group e.g., formyl group, C i - 6 alkyl one carbonyl group, C! _ 6- anoloxycarbonyl group, benzoyl group, C 7 ⁇
- aralkyl monocarbonyl group C 7 _! 3 aralkyloxycarbonyl group, trityl group, phthaloyl group, N, N-dimethylaminomethylene group, silyl group (eg, trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyldimethylsilyl, tert-butyldimethylsilyl), C 2 — 6- alkylene group. These groups may be substituted with 1 to 3 halogen atoms, 6 alkoxy groups or nitro groups.
- the protecting group of the carboxyl group for example, - 6 alkyl group, C 7 - 1 3 Ararukiru group, phenyl group, trityl group, a silyl group (e.g., trimethyl silyl, tri E chill Siri Honoré, Jimechirufue - Rushiriru, tert- Puchirujime Chirushiriru , tert- butyl GETS chill silyl), C 2 - and the like 6 alkenyl group.
- These groups may be substituted with 1 to 3 halogen atoms, a 6- alkoxy group, a -tro group or the like.
- Examples of protecting groups for human Dorokishi group e.g., - 6 alkyl group, phenylene group, a trityl group, C 7 - i 3 Ararukiru group, formyl group, - 6 alkyl Honoré one carbonyl group, Benzoiru group, C 7 _ J 3 Aralkyl monocarbonyl group
- Examples of the protecting group for the carbocycle include cyclic acetals (eg, 1, 3. monodioxane), acyclic acetals (eg, di-C, 6 alkyl alkylator). E).
- protecting groups can be introduced or removed by methods known per se, such as Protective Groups in Organic Synthesis (
- the compound represented by the formula (IV) when the raw material compound can form a salt, the compound may be used as a salt.
- examples of such salts include the same salts as the salts of the compound represented by the formula (I).
- N- [5- (aminomethyl) -6-isoptyl-2-methyl-4- (4-methylphenyl) pyridin-3-yl] isoxazole-4-carboxamide is preferred.
- the knee insulin content-increasing agent of the present invention (hereinafter sometimes abbreviated as the agent of the present invention) combines a non-insulin secretion type hypoglycemic agent, which is an active ingredient, and a DPP-IV inhibitor. Can be obtained. These active ingredients may be formulated separately or simultaneously with a pharmacologically acceptable carrier.
- the pharmacologically acceptable carrier various organic or inorganic carrier substances conventionally used as pharmaceutical materials are used, and excipients, lubricants, binders, disintegrating agents in solid preparations; liquid preparations It is formulated as a solvent, solubilizer, suspending agent, tonicity agent, buffering agent, soothing agent, etc. If necessary, formulation additives such as preservatives, antioxidants, coloring agents, sweeteners, etc. can be used.
- Suitable excipients include lactose, sucrose, D-mannitol, D-sol Bitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, carboxymethylcellulose sodium, gum arabic, pullulan, light anhydrous caustic acid, synthetic silicate aluminum, metasilicate aluminate Examples include magnesium.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- Preferred examples of the binder include a-modified starch, sucrose, gelatin, arabic gum, methinolecellulose, carboxymethylenosesenolose, carboxymethylcellulose sodium, crystalline cellulose, sucrose, D-mannitol, trehalose, dex Examples include trinine, punoleran, hydroxypropynolesanolose, hydroxypropylmethylcellulose, and polypyrrole pyrrolidone.
- disintegrants include lactose, birch, starch, carboxymethyl senorelose, canoleboxymethy / resenolellose canoleum, cross-strength sodium melose, sodium carboxymethyl starch, light anhydrous key acid, low substituted hydride
- examples include roxypropylcellulose.
- the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.
- solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, trenorose, benzenole benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, citrate
- solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, trenorose, benzenole benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, citrate
- solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, trenorose, benzenole benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, citrate
- examples include sodium, sodium salicylate, and sodium acetate.
- suspending agent examples include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzenium chloride, and glycerin monostearate; High hydrophilicity such as polybial alcohol, polybylpyrrolidone, carboxymethylenosenorelose sodium, methinoresenorelose, hydroxymethynorenosellose, hydroxichechinoselenose, hydroxypropynolesenolate Molecule: polysorbates, polyoxyethylene hydrogenated castor oil, and the like.
- surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzenium chloride, and glycerin monostearate
- High hydrophilicity such as polybial alcohol, polybylpyrrolidone, carboxy
- the tonicity agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, pudou sugar and the like.
- buffers such as phosphate, acetate, carbonate, kenate and the like.
- Preferable examples of the soothing agent include benzyl alcohol.
- Preferable examples of the preservative include parabenzoic acid esters, chlorobutanol and benzyl alcohol, phenetinoreanolol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite and ascorbate.
- colorants include water-soluble edible tar dyes (eg, edible dyes such as edible red Nos. 2 and 3, edible yellows Nos. 4 and 5, and edible blue No. 1 Oppi 2), water Insoluble lake dye (eg, aluminum of the water-soluble edible tar dye) Nyum salt), natural pigments (eg, j3—power rotin, chlorophyll, bengara, yellow ferric oxide).
- water-soluble edible tar dyes eg, edible dyes such as edible red Nos. 2 and 3, edible yellows Nos. 4 and 5, and edible blue No. 1 Oppi 2
- water Insoluble lake dye eg, aluminum of the water-soluble edible tar dye
- Nyum salt eg, aluminum of the water-soluble edible tar dye
- natural pigments eg, j3—power rotin, chlorophyll, bengara, yellow ferric oxide.
- sweetening agent examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- dosage form of the agent of the present invention examples include tablets (including sublingual tablets and orally disintegrating tablets), capsules (including soft capsules and microcapsules), granules, powders, troches, syrups, emulsions, and suspensions.
- Oral preparations such as turbid agents; and injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), external preparations (eg, nasal preparations, transdermal preparations, ointments) ), Suppositories (eg, rectal suppositories, vaginal suppositories), pellets, drops, eye drops, transpulmonary agents (inhalants), and other parenteral agents.
- These preparations may be controlled-release preparations such as immediate-release preparations or sustained-release preparations (eg, sustained-release microcapsules).
- oral preparations that are excellent in convenience or compliance are preferred.
- the agent of the present invention can be produced by a method commonly used in the field of pharmaceutical technology, for example, a method described in the Japanese Pharmacopoeia.
- the content of the active ingredient (non-insulin secretion type hypoglycemic agent and / or DPP-IV inhibitor) in the agent of the present invention varies depending on the type of active ingredient, the size of the preparation, etc. % By weight, preferably 5 to 80% by weight.
- the compounding ratio of the non-insulin secretion type hypoglycemic agent and the DPP-IV inhibitor can be appropriately selected depending on the administration subject, administration route, target disease, dosage form, combination of agents and the like.
- a DPP-IV inhibitor is usually used in an amount of about 0.005 to 200 parts by weight, preferably about 0.001 to 100 parts by weight per 1 part by weight of a non-insulin secretion hypoglycemic agent. That's fine.
- the administration form of the agent of the present invention is not particularly limited as long as a non-insulin secretion type hypoglycemic agent and a DPP-IV inhibitor are combined at the time of administration.
- Examples of such administration forms include 1) administration of a single preparation obtained by simultaneously formulating a non-insulin secretion hypoglycemic agent and a DPP-IV inhibitor, and 2) non-insulin secretion hypoglycemic reduction.
- Non-insulin secretion type hypoglycemic agent and DPP-IV inhibitor are separately formulated, and two formulations are administered simultaneously by different administration routes, 5) Non-insulin secretion type hypoglycemic agent Administration of drugs and DPP-IV inhibitors separately in different administration routes at different time intervals (eg, non-insulin secretion hypoglycemic drugs, DPP-IV inhibitors Administration in the order, or administration in the reverse order).
- the agent of the present invention should be safely administered orally or parenterally to mammals (eg, humans, mice, rats, rabbits, inu, cats, mice, horses, pigs, monkeys). Can do.
- mammals eg, humans, mice, rats, rabbits, inu, cats, mice, horses, pigs, monkeys.
- the dose of the agent of the present invention may be based on the dose of the active ingredient non-insulin secretion type hypoglycemic agent or DPP-IV inhibitor, and the administration subject, administration route, target disease, dosage form, drug Depending on the combination of these, etc., it can be appropriately selected.
- the doses of non-insulin-secreting hypoglycemic drugs and DPP-IV inhibitors can be appropriately selected based on clinically used doses.
- the dose of the non-insulin secretion type hypoglycemic drug is usually 0.01 to 500 mgZ day, preferably 0.1 to 100 mg / day, for example, per adult patient (body weight 60 kg). This amount can also be administered in 2 to 3 divided doses per day.
- the dose of the insulin sensitizer is usually 0.1 to: LOOmg / day, preferably per adult patient (body weight 60 kg) it is a l ⁇ 60m g date.
- the effective amount of pioglitazone hydrochloride is usually 7.5-60 mg / day, preferably 15-45 mg Z day per adult patient (body weight 60 kg). is there.
- the effective amount of rosiglitazone maleate is usually llSnigZ days, preferably S SmgZ days, per adult patient (body weight 60 kg).
- Biguanide as non-insulin-secreting hypoglycemic agent preferably hydrochloric acid Main Tohu. Orumin
- the dosage of Biguanai de agent preferably hydrochloric main xanthohumol Orumin
- an adult patient body weight 60 kg
- the dose of the DPP-IV inhibitor is, for example, generally 0.01 to 1 day; preferably 1 to 500 mg / day per adult patient (body weight 60 kg). This amount can also be administered in 2 to 3 divided doses per day.
- the agent of the present invention has an enhanced action of increasing the insulin content compared to the non-insulin secretion type hypoglycemic drug or DPP-IV inhibitor administered alone.
- “knee insulin content” means the insulin content in the spleen.
- “Knee insulin content” is determined by measuring insulin extracted from the knee tissue of a subject animal according to a method known per se according to a method known per se. Insulin can be measured by any method as long as insulin can be measured, specifically, radioimmunoassay or enzaimimnoassay using one kind of anti-insulin antibody; Alternatively, an enzyme immunoassay using two anti-insulin antibodies with different epitopes is used.
- Knee insulin content can also be evaluated using knee insulin mRNA and knee cell volume as an index.
- the knee insulin mRNA and the amount of knee cells can be measured using a method known per se.
- ⁇ The method of tissue staining using an insulin antibody is generally used to measure the amount of 3 cells.
- in situ hybridization that detects insulin mRNA and protein that is selectively expressed in knee j8 cells.
- a method may be used in which an endogenous or exogenous substance that binds with high specificity is labeled, and the labeled activity is measured after the labeled substance is administered to a test animal.
- the endogenous or exogenous substance can be labeled with, for example, a radioisotope, a luminescent substance (low molecular compound or protein such as luciferase or GFP), a fluorescent substance, or the like.
- insulin content is used to estimate the amount of remaining knee cells. It can also be evaluated by a known method. Examples of the method include a method of measuring active insulin or C-peptide in the blood by performing a Dalgon test. Alternatively, instead of the glucagon tolerance test, a glucose tolerance test can be performed to measure active insulin or C-peptide in the blood. It is also possible to measure active insulin or C-peptide in the blood without performing a glucagon tolerance test.
- the amount of the drug used can be reduced compared to when each drug is used alone, and these drugs are not preferred. If it has an action (eg, weight gain action), such action can be reduced.
- the agent of the present invention has an enhanced blood glucose lowering effect, glycation to hemoglobin lowering effect, blood insulin level, as compared with non-insulin secretion type hypoglycemic or DPP-IV inhibitor alone. Has an ascending action.
- the agent of the present invention is used for diabetes (eg, type 1 diabetes, type 2 diabetes, 1.5 type diabetes (LADA (Latent Autoimmune Diabetes in Adults)), gestational diabetes, insulin secretion deficiency type diabetes, obesity type diabetes, Impaired Glucose Tolerance (IGT), IFG (Impaired Fasting Glucose), IFG (Impaired Fasting Glycaemia)], diabetic complications [eg, neuropathy, nephropathy, retinopathy, cataract, macrovascular disorder , Arteriosclerosis, osteopenia, diabetic hyperosmotic coma, infection (eg, respiratory infection, urinary tract infection, gastrointestinal infection, skin soft tissue infection, leg infection), diabetic It is useful for the prevention and treatment of gangrene, xerostomia, hearing loss, cerebrovascular disorder, peripheral blood circulation disorder, etc. Furthermore, the agent of the present invention can suppress the progression from diabetes to diabetic complications (preferably diabetic neuropathy, diabetic nephropathy, diabetic retinopathy,
- the agent of the present invention is effective against mammals whose blood glucose level is higher than normal because it decreases the insulin content due to hyperglycemia itself. Can be used to normalize blood glucose levels. Furthermore, the agent of the present invention can be used among mammals whose blood glucose level is higher than normal. ⁇ It is useful for mammals whose function is reduced and insulin secretion is incomplete.
- the agent of the present invention can increase the amount of insulin mRNA.
- the agent of the present invention suppresses knee fatigue caused by glycotoxicity, lipotoxicity, glycolipotoxicity, oxidative stress, or endoplasmic reticulum stress due to diabetes, and is an important function of knee cells. Retains dependent insulin secretion capacity.
- the agent of the present invention can suppress knee
- the agent of the present invention should be used in combination with other drugs (hereinafter abbreviated as concomitant drugs), as long as it does not adversely affect the active ingredient non-insulin secretion type hypoglycemic drug OPP DPP IV inhibitor. Can do.
- concomitant drugs hereinafter abbreviated as concomitant drugs
- examples of the “concomitant drug” include a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobesity agent, a diuretic agent, an antithrombotic agent, etc.
- the administration timing of the drug is not limited, and these may be administered simultaneously to the administration subject, or may be administered with a time difference.
- the agent of the present invention and the concomitant drug may be administered as two types of preparations containing each active ingredient, or may be administered as a single preparation containing both active ingredients.
- the dose of the concomitant drug can be appropriately selected based on the clinically used dose.
- the mixing ratio of the agent of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination and the like.
- the concomitant drug may be used in an amount of 0.01 to 100 parts by weight per 1 part by weight of the active ingredient of the agent of the present invention.
- the anti-diabetic agent examples include insulin preparations (eg, ushi, animal insulin preparations extracted from pig knees; human insulin preparations synthesized by genetic engineering using Escherichia coli or yeast; insulin zinc; protami Insulin zinc; Fragments or derivatives of insulin (eg, INS 1 1)), GLP-1 receptor agonist [eg, GLP-1, NN-2211, AC-2993 ( exendin- 4), BIM- 51077, Aib (8, 35) hGLP- 1 (7, 37) NH 2], Ami Rinago two strike (e.g., pramlintide), Fosufochi port Shin phosphatase INHIBITOR (e.g., sodium vanadate Um), 3agost (eg, AJ-9677), gluconeogenesis inhibitor (eg, glycogen phosphorylase inhibitor, glucose-6-phosphatase inhibitor, glucagon antagonist), SGLT (sodium-glucose cotransporter) inhibition Agent
- the therapeutic agents for diabetic complications include aldose reductase inhibitors (eg, torrestat, enolrestat, zenarestat, zoponolestat, minarerestat, fidarestat, CT-112, larestat (AS-3 2 0 1))
- Neurotrophic factors and their increasing agents eg, NGF, NT-3, BDNF, W001 / 14372 neurotrophin production / secretion promoters (eg 4 1 (4 cyclophenyl) 1 2 — (2-Methyl _ 1 imidazolyl) _ 5— [3— (2-Methylphenoxy) propyl] oxazole, etc.) ruboxistaurin mesylate)
- AGEP and harmful agents eg, ALT946, pimagedin, N-phenacyl thiazolium bromide (ALT766), EX0-226), active oxygen scavengers (eg, chi Acid), cerebral vasodilators (
- Antihyperlipidemic agents include HM G—CoA reductase inhibitors (eg, bravastatin, sympastatin, oral pastatin, atonolepastatin, funolepastatin, itapastatin, rospastatin, pitapastatin or their salts ( Eg, sodium salt, calcium salt))), squalene synthase inhibitor (eg, compound described in W097 / 10224, for example, N— [[(3R, 5S)-1- (3-acetoxy-2, 2-dimethyl Propyl) -7-chloro-5- (2,3-dimethoxyphenyl) -2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl] acetyl ] Piperidine-4-acetic acid), fibrate compounds (eg, bezafibrate, Clofibrate, simfibrate, clinofibrate), ACAT inhibitor (eg, Avasimi
- Antihypertensive agents include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril), angiotensin II antagonists (eg, candesanoletan, nrexetinore, oral sanoretan, eprosanoletan, panoresanoretane, tenoremisoletane, Thassosanoletan, 1- [[2 '-(2, 5-Dihydro-5 -oxo-4H- 1, 2, 4-oxadiazol-3-yl) biphenyl-4_yl] methyl]-2- Ethoxy-1H-benzimidazole-7-carboxylic acid), calcium antagonists (eg, manidipine, ephedipine, amlodipine, efonidipine, dicanodipine), potassium channel openers (eg, levcromacarim, L-27152, AL 0671, NIP) -121) and clo
- Anti-obesity agents include, for example, central anti-obesity drugs (eg, dexfenfluramine, fenfluramine, phentermine, sibutramine, ampheturamon, dexamphetamine, mazindol, phenylpropanolamine, kubenbenzolex MCH receptor antagonists (eg, SB-568849; SNAP-7941; compounds included in W001 / 82925 and W001 / 87834); neuropeptide Y antagonists (eg, CP-422935); cannabinoid receptor antagonists ( Eg, SR-141716, SR-147778); ghrelin antagonist; knee lipase inhibitor (eg, orlistat, ATL-962), j3 3 agonist (eg, AJ-9677), peptide anorectic agent (eg, , Leptin, CNTF (ciliary neurotrophic factor)), cholecystokininagost (eg,
- diuretics examples include xanthine derivatives (eg, sodium salicylate theopromine, calcium salicylate theopromine), thiazide preparations (eg, ethiazide, cyclopenthiazide, trichloromethiazide, hydrotalo'thiazide, hydrof ⁇ / methiazide , Bennore Lech Mouth thiazide, Penflutizide, polythiazide, methiclotiazide), anti-aldosterone formulation (eg, spironolatatone, triamterene), carbonic anhydrase inhibitor (eg, acetazolide), chlorobenzenesulfonamide (eg, chlorthalidone, mefluside, indamide) ), Azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, furosemide and the like.
- xanthine derivatives
- Antithrombotic agents include, for example, heparin (eg, heparin sodium, heparincanoleum, dalteparin sodium), ⁇ rufaline (eg, ⁇ rufarin potassium), antithrombin agent (eg, argatroban) )), Thrombolytic drugs (eg, urokinase, tisokinase, anoleplase, nateplase)
- heparin eg, heparin sodium, heparincanoleum, dalteparin sodium
- ⁇ rufaline eg, ⁇ rufarin potassium
- antithrombin agent eg, argatroban
- Thrombolytic drugs eg, urokinase, tisokinase, anoleplase, nateplase
- the DPP-IV inhibitor is a GLP-1 receptor agonist [eg, GLP-1, ⁇ -2211, AC-2993 (exendin-4), BIM-51077, Aib (8, 35) When replaced with hGLP-1 (7, 37) NH 2 ], enhanced insulin content-increasing action, hypoglycemic action, glycated hemoglobin-lowering action, blood insulin-increasing action, etc.
- the GLP-1 receptor agonist can be formulated in the same manner as the DPP-IV inhibitor in the agent of the present invention and administered to a mammal.
- the present invention further relates to “an agent for enhancing acupuncture protective action of a DPP-IV inhibitor, which contains a non-insulin secretion type hypoglycemic agent”. That is, by using a combination of a non-insulin secretion type hypoglycemic agent and a DPP-IV inhibitor, it is possible to enhance the wrinkle protecting action of the DPP-IV inhibitor.
- non-insulin secretion type hypoglycemic drugs and DPP-IV inhibitors Those exemplified in the above-mentioned knee insulin content-increasing agent can be mentioned, and the dosage thereof is the same as that in the above-mentioned knee insulin content-increasing agent.
- knee protective effects include knee insulin content increasing effect, prevention of hemorrhoid fatigue-therapeutic effect, knee (i3 cell) function improving effect, knee (cell) regeneration effect, knee cell) regeneration promoting effect, glycotoxicity inhibiting effect, These include lipotoxicity inhibitory action, glycolipotoxicity inhibitory action, oxidative stress inhibitory action, endoplasmic reticulum stress inhibitory action, ⁇ cell apoptosis inhibitory action, and insulin secretion enhancing action.
- the insulin secretion enhancing effect can be evaluated by calculating the ratio of the plasma insulin level to the blood clot glucose level in the administration subject, and the increase in the “plasmin insulin level plasma glucose level” It means enhancement.
- the protective action is preferably an increase in the content of polyurethane.
- DPP-IV inhibitor-enhancing agent containing non-insulin-secreting hypoglycemic agent is manufactured using non-insulin-secreting hypoglycemic agent in the same manner as the above-mentioned agent for increasing insulin content. It can be used for the prevention and treatment of diabetes and diabetic complications.
- a DPP-IV inhibitor-enhancing agent containing a non-insulin secretion-type hypoglycemic agent is administered in the same manner as the above-mentioned knee insulin content-increasing agent.
- Administration of the lowering drug and the DPP-IV inhibitor at the same time or at different times may be used.
- the “KPP-protecting agent for DPP-IV inhibitor containing a non-insulin secretion-type hypoglycemic agent” can be used in combination with the aforementioned concomitant drug.
- the present invention further provides “DPP-IV inhibition”
- the present invention relates to an agent for enhancing acupuncture protection action of a non-insulin secretion-type hypoglycemic agent containing a drug ”. That is, by using a combination of a DPP-IV inhibitor and a non-insulin secretion type hypoglycemic agent, the wrinkle protection action of the non-insulin secretion type hypoglycemic agent can be enhanced.
- examples of the DPP-IV inhibitor, the non-insulin secretion type hypoglycemic agent and the sputum protective action include the same as those mentioned above, and the DPP-IV inhibitor and the non-insulin secretion type hypoglycemic agent
- the dose is the same as that of the knee insulin content increasing agent. It is like.
- a non-insulin secretory ifiL sugar-lowering agent containing a DPP_IV inhibitor is manufactured using a DPP-IV inhibitor in the same manner as the above-mentioned agent for increasing the insulin content. Can be used for the prevention and treatment of diabetes, diabetic complications, etc.
- a non-insulin secretion-type hypoglycemic agent-enhancing agent containing a DPP-IV inhibitor is the same as in the case of the above-mentioned knee insulin content-increasing agent.
- Either a hypoglycemic drug and a DPP-IV inhibitor may be administered simultaneously or with a time difference.
- the “Knee-protective effect enhancer of non-insulin secretion type hypoglycemic agent containing DPP-IV inhibitor” can be used in combination with the above-mentioned concomitant drug.
- the present invention further includes “non-insulin secretion”.
- a DPP-IV inhibitor administered to a mammal and a method for synergistically protecting the mammal's knee in comparison with the single administration of these drugs.
- a synergistic knee protection effect can be obtained by using a combination of a non-insulin secretion type hypoglycemic agent and a DPP-IV inhibitor.
- examples of the non-insulin secretion type hypoglycemic agent, the DPP-IV inhibitor and the mammal include those exemplified in the above-mentioned knee insulin content increasing agent, and these doses are also the case of the above knee insulin content increasing agent. It is the same.
- the above-mentioned “synergistic wrinkle-protecting effect” means “the knee-protecting effect obtained when the non-insulin-secreting hypoglycemic agent” is administered alone ”and“ the wrinkle-protecting effect obtained when the DPP-IV inhibitor is administered alone ” Means better knee protection than the sum.
- ⁇ protection effect means the effect of increasing knee insulin content, prevention of ⁇ fatigue, treatment effect, knee (cell) function improvement effect, knee (j8 cell) regeneration effect, knee (; 8 cell) regeneration promotion effect, Glycotoxicity inhibitory effect, lipotoxicity inhibitory effect, glycolipotoxicity inhibitory effect, oxidative stress inhibitory effect, endoplasmic reticulum stress inhibitory effect, ⁇ ; 8-cell apoptosis inhibitory effect, insulin secretory power enhancing effect, etc.
- the wrinkle protection effect is preferably a wrinkle content increasing effect.
- the administration mode of the non-insulin secretion type hypoglycemic agent and the DPP-IV inhibitor is not particularly limited, and it may be administered simultaneously or at a time interval.
- non-insulin secretion type hypoglycemic agent OPP DPP-IV inhibitor can also be used in combination with the aforementioned concomitant drug.
- the present invention will be described in more detail with reference to the following reference examples, examples and experimental examples, but these are not intended to limit the present invention, and may be changed without departing from the scope of the present invention. .
- Reference Example 1 5- (Aminomethyl) _6-isobutyl-2-methyl-4- (4-methylphenyl) nicotinic acid methylolate
- mice 32 mice were divided into 4 groups (8 mice each) in groups A to D, and A group (control group) was powdered feed (trade name: CE-2, Nippon Claire, and so on)
- a group control group was powdered feed (trade name: CE-2, Nippon Claire, and so on)
- Group B contains a powdered feed containing pioglitazone hydrochloride (0.01 (w / w)% as pioglitazone)
- Group C contains 1Z2 fumarate of Compound A (0.03 (w / w) as Aich Compound A). Powdered feed
- Group D contains pioglitazone hydrochloride (0.01 (w / w)% as pioglitazone) and 1Z2 fumarate of compound A (0.03 (w / w)% as compound A). For 3 consecutive weeks.
- mice were given a powdered diet for 3 consecutive weeks, and this was designated as group E (normal group).
- the insulin content was measured as follows.
- the mouse knee was ruptured in 10 times its weight in 75% ethanol (containing 0.15 M hydrochloric acid).
- the obtained crushed liquid was allowed to stand for a while under light shielding at 4 ° C and then centrifuged at 15000 rpm for 5 minutes.
- the obtained upper arm is diluted appropriately with PBS (-) (phosphate buffered saline) containing 0.1% BSA (usi serum albumin), and then the insulin content in the diluted solution is the same as the above plasma insulin level. Insulin content per tissue weight was calculated.
- the results are shown in [Table 1] to [Table 4], respectively.
- Group B (Piodaritazone) 411.0 ⁇ 54.4 Group C (Compound A) 502.0 + 54.3
- Group D (Piodaritazone + Compound A) 267.1 ⁇ 89.7
- Group E (Normal group) ⁇ 146.4 ⁇ 20.1
- Group B (Piodaritazone) 2314.2 Sat 1285.4
- Group C (Compound A) 918.4 Sat 328.6
- Group D (Piodaritazone + Compound A) 4962.7 ⁇ 2441.0
- Group E (Normal Group) _ 4823.6 Sat 754.9
- Group B (Piodaritazone) 289.2 ⁇ 261.8
- Group C (Compound A) 135.5 ⁇ 115.4
- Group D Plasma insulin / plasma glucose level (; u U / mg) Plasma insulin / plasma glucose level
- Group E (normal group) 37. 4 people 15. 9
- Group G contains a powdered feed containing piodaritazone hydrochloride (0.01 (w / V)% as piodaritazone)
- Group H contains a powdered feed containing vildagliptin (0, 03 (w / w)%)
- Group I included piodaritazone hydrochloride (0.01 (w / w)% as piodaritazone) and Powdered feed containing irdaglibutin (0.03 (w / W )%) was fed for 5 consecutive weeks each.
- mice were given a powdered diet for 5 consecutive weeks, which was designated as group J (normal group).
- Knee insulin content (/ zU / mg tissue) Knee insulin content
- Group G (Piodaritazone) 834.7 ⁇ 275.3
- Group H (Wildagliptin) 559.2 ⁇ 169.2
- Group I (Piodaritazone + Wildagliptin) 1472.7 Sat 661.0
- Group G (Pioglitazone) 200.2 ⁇ 78.0
- Group H (Wildagliptin) 80.2 ⁇ 44.5
- Group I (Piodaritazone + Vildagliptin) 573.3 ⁇ 381.3 _!
- db / db mice 32 mice were divided into 4 groups (8 mice each) in the K to N group, and the K group (control group) was a powdered feed (trade name: CE-2, Nippon Claire, and so on)
- K group control group
- CE-2 powdered feed
- Group L contains a powdered feed containing piodaritazone hydrochloride (0.01 (w / w)% as piodaritazone)
- Group M is a powdered feed containing sitagribtin hydrochloride (0.03 (w / V)% as sitagliptin)
- Group N was given a powdered diet containing piodaritazone hydrochloride (0.01 (w / w)% as piodaritazone) and sitagribtin hydrochloride (0.03 (w / W )% as sitagribtin) for 4 consecutive weeks. It was.
- mice were given a powdered diet for 4 consecutive weeks, and this was designated as group O (normal group).
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/660,939 US20070259927A1 (en) | 2004-08-26 | 2005-08-25 | Remedy for Diabetes |
JP2006532768A JP4854511B2 (ja) | 2004-08-26 | 2005-08-25 | 糖尿病治療剤 |
EP05777050A EP1782832A4 (en) | 2004-08-26 | 2005-08-25 | MEANS FOR THE TREATMENT OF DIABETES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004246620 | 2004-08-26 | ||
JP2004-246620 | 2004-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022428A1 true WO2006022428A1 (ja) | 2006-03-02 |
Family
ID=35967622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015956 WO2006022428A1 (ja) | 2004-08-26 | 2005-08-25 | 糖尿病治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070259927A1 (ja) |
EP (1) | EP1782832A4 (ja) |
JP (1) | JP4854511B2 (ja) |
WO (1) | WO2006022428A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007035665A1 (en) * | 2005-09-20 | 2007-03-29 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
WO2009128360A1 (ja) * | 2008-04-18 | 2009-10-22 | 大日本住友製薬株式会社 | 糖尿病治療剤 |
US7820666B2 (en) | 2007-05-08 | 2010-10-26 | Concert Pharmaceuticals, Inc. | Tetrahydrotriazolopyrazine derivatives and uses thereof |
WO2012057343A1 (ja) * | 2010-10-28 | 2012-05-03 | 国立大学法人九州大学 | Nad(p)hオキシダーゼ阻害剤、酸化ストレス疾患治療薬、酸化ストレス疾患治療方法及びスクリーニング方法 |
CN101889633B (zh) * | 2009-12-31 | 2012-11-07 | 华南农业大学 | 盐酸吡咯列酮在禽畜饲料添加剂中的应用 |
JP2015091864A (ja) * | 2005-06-10 | 2015-05-14 | ノバルティス アーゲー | 放出が改良された1−[(3−ヒドロキシ−アダマント−1−イルアミノ)−アセチル]−ピロリジン−2(s)−カルボニトリル製剤 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
JP5094416B2 (ja) * | 2005-12-28 | 2012-12-12 | 武田薬品工業株式会社 | 糖尿病治療剤 |
CN103951667A (zh) | 2006-05-04 | 2014-07-30 | 勃林格殷格翰国际有限公司 | 多晶型 |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US8168391B2 (en) | 2007-11-07 | 2012-05-01 | Burnham Institute For Medical Research | Method for modulating insulin production |
JP2011510986A (ja) * | 2008-02-05 | 2011-04-07 | メルク・シャープ・エンド・ドーム・コーポレイション | メトホルミン及びジペプチジルペプチダーゼ−iv阻害剤の併用医薬組成物 |
WO2009111200A1 (en) * | 2008-03-04 | 2009-09-11 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
MX2011006713A (es) | 2008-12-23 | 2011-07-13 | Boehringer Ingelheim Int | Formas salinas de compuesto organico. |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
EP2442806A1 (en) * | 2009-06-15 | 2012-04-25 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
KR20230021159A (ko) | 2009-11-27 | 2023-02-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
US8458749B2 (en) * | 2009-12-02 | 2013-06-04 | At&T Intellectual Property I, Lp | System and method for an interactive internet radio application in an internet protocol television system |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8907086B2 (en) | 2011-03-03 | 2014-12-09 | Merck Sharp & Dohme Corp. | Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
HUE043540T2 (hu) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003520226A (ja) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物 |
JP2003523396A (ja) * | 2000-02-25 | 2003-08-05 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性の抑制 |
JP2003528135A (ja) * | 2000-03-31 | 2003-09-24 | プロバイオドラッグ アーゲー | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 |
JP2003535898A (ja) * | 2000-06-19 | 2003-12-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 真性糖尿病の治療用のジペプチジルペプチダーゼiv阻害剤および他の抗糖尿病剤の組み合わせ |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US7078397B2 (en) * | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
EP1557165A4 (en) * | 2002-09-26 | 2008-12-03 | Eisai R&D Man Co Ltd | COMBINED MEDICINE |
PE20050444A1 (es) * | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
-
2005
- 2005-08-25 US US11/660,939 patent/US20070259927A1/en not_active Abandoned
- 2005-08-25 JP JP2006532768A patent/JP4854511B2/ja active Active
- 2005-08-25 WO PCT/JP2005/015956 patent/WO2006022428A1/ja active Application Filing
- 2005-08-25 EP EP05777050A patent/EP1782832A4/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003520226A (ja) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物 |
JP2003523396A (ja) * | 2000-02-25 | 2003-08-05 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性の抑制 |
JP2003528135A (ja) * | 2000-03-31 | 2003-09-24 | プロバイオドラッグ アーゲー | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 |
JP2003535898A (ja) * | 2000-06-19 | 2003-12-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 真性糖尿病の治療用のジペプチジルペプチダーゼiv阻害剤および他の抗糖尿病剤の組み合わせ |
Non-Patent Citations (5)
Title |
---|
FINEGOOD DT ET AL: "Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.", DIABETES., vol. 50, no. 5, 2001, pages 1021 - 1029, XP002993898 * |
ISHIDA H ET AL: "Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.", METABOLISM., vol. 53, no. 4, 2004, pages 488 - 494, XP002993899 * |
POSPISILIK JA ET AL: "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates Beta-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats.", DIABETES., vol. 52, no. 3, 2003, pages 741 - 750, XP002260040 * |
REIMER MK ET AL: "Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.", EUR J ENDOCRINOL., vol. 146, no. 5, 2002, pages 717 - 727, XP002993897 * |
See also references of EP1782832A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015091864A (ja) * | 2005-06-10 | 2015-05-14 | ノバルティス アーゲー | 放出が改良された1−[(3−ヒドロキシ−アダマント−1−イルアミノ)−アセチル]−ピロリジン−2(s)−カルボニトリル製剤 |
JP2016222675A (ja) * | 2005-06-10 | 2016-12-28 | ノバルティス アーゲー | 放出が改良された1−[(3−ヒドロキシ−アダマント−1−イルアミノ)−アセチル]−ピロリジン−2(s)−カルボニトリル製剤 |
JP2020055816A (ja) * | 2005-06-10 | 2020-04-09 | ノバルティス アーゲー | 放出が改良された1−[(3−ヒドロキシ−アダマント−1−イルアミノ)−アセチル]−ピロリジン−2(s)−カルボニトリル製剤 |
WO2007035665A1 (en) * | 2005-09-20 | 2007-03-29 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
US7820666B2 (en) | 2007-05-08 | 2010-10-26 | Concert Pharmaceuticals, Inc. | Tetrahydrotriazolopyrazine derivatives and uses thereof |
WO2009128360A1 (ja) * | 2008-04-18 | 2009-10-22 | 大日本住友製薬株式会社 | 糖尿病治療剤 |
CN101889633B (zh) * | 2009-12-31 | 2012-11-07 | 华南农业大学 | 盐酸吡咯列酮在禽畜饲料添加剂中的应用 |
WO2012057343A1 (ja) * | 2010-10-28 | 2012-05-03 | 国立大学法人九州大学 | Nad(p)hオキシダーゼ阻害剤、酸化ストレス疾患治療薬、酸化ストレス疾患治療方法及びスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
US20070259927A1 (en) | 2007-11-08 |
EP1782832A4 (en) | 2009-08-26 |
EP1782832A1 (en) | 2007-05-09 |
JPWO2006022428A1 (ja) | 2008-05-08 |
JP4854511B2 (ja) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006022428A1 (ja) | 糖尿病治療剤 | |
EP1671649B1 (en) | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure | |
US7414071B2 (en) | Methods of treatment with selective EP4 receptor agonists | |
US20060039974A1 (en) | Sustained release preparation | |
JP5968455B2 (ja) | チエノ[3,2−d]ピリミジン−4−オン系化合物、その製造方法、医薬品組成物および用途 | |
CN101646653A (zh) | 作为ppar-y的部分激动剂的稠环化合物 | |
JP2023513272A (ja) | ヘテロ環glp-1アゴニスト | |
TW200523252A (en) | Pyridine compounds | |
WO2007074884A1 (ja) | 糖尿病治療剤 | |
BR112020022340A2 (pt) | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas | |
TW201835081A (zh) | 具有體抑素受體促效活性之化合物及其醫藥用途 | |
US8304428B2 (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
US20230201185A1 (en) | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
US20170065608A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
WO2009099171A1 (ja) | 医薬 | |
WO2009099172A1 (ja) | 医薬 | |
KR20200139702A (ko) | 칼페인 조정자 및 그 치료학적 용도 | |
JP2004123738A (ja) | 徐放性製剤 | |
KR20210039417A (ko) | 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법 | |
WO2001072695A1 (fr) | Inhibiteurs de la neovascularisation | |
ES2390053T3 (es) | Derivado de ácido fenilacético, procedimiento para producir el mismo y uso | |
TW201900616A (zh) | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 | |
JP2008285452A (ja) | PPARα/γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 | |
CN101732718A (zh) | 包含ncx抑制剂的药物组合物 | |
WO2023228023A1 (en) | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532768 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11660939 Country of ref document: US Ref document number: 2005777050 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005777050 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11660939 Country of ref document: US |